Drug Profile
Research programme: venomics - QRxPharma
Alternative Names: Haempatch; Q 70050; Q 8008; Q 8009; Q 8010; TextilininLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator QRxPharma
- Developer QRxPharma; The University of Queensland
- Class Enzymes; Peptides; Venoms
- Mechanism of Action Plasmin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haemorrhage
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Haemorrhage in Australia (Parenteral)
- 31 Dec 2008 Early research is ongoing in Australia
- 03 Feb 2005 Early research in Haemorrhage in Australia (Parenteral)